Alteogen Inc.
196170
Classement en actions
#1912
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters,... ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
Prix de l'action
$159.04
Capitalisation boursière
$11.07B
Changement (1 jour)
-2.95%
Changement (1 an)
-48.94%
Pays
KR
Échange Alteogen Inc. (196170)
Catégorie
Healthcare
EPS pour Alteogen Inc. (196170)
EPS au June 2026 TTM : $2.18
Selon les derniers rapports financiers et le cours de l'action de Alteogen Inc., l’EPS actuel de la société (TTM) est de $2.18. À la fin de 2023, la société avait un EPS de $-0.05 une diminution par rapport à celui de 2022, qui était de $-0.13.
Historique de l'EPS de Alteogen Inc. de 2012 à 2026
EPS à la fin de chaque année
| Année | EPS | Changez |
|---|---|---|
| 2026 (TTM) | $2.18 | 172.34% |
| 2024 | $0.80 | -1,681.75% |
| 2023 | $-0.05 | -59.97% |
| 2022 | $-0.13 | 44.88% |
| 2021 | $-0.09 | -54.97% |
| 2020 | $-0.19 | 1,419.69% |
| 2019 | $-0.01 | -90.64% |
| 2018 | $-0.14 | -12.79% |
| 2017 | $-0.16 | 126.82% |
| 2016 | $-0.07 | -382.30% |
| 2015 | $0.02 | -10.00% |
| 2014 | $0.03 | -66.17% |
| 2013 | $0.08 | -1.60% |
| 2012 | $0.08 | 0.00% |
EPS pour des entreprises ou concurrents similaires
| Entreprise | EPS | Différence d’EPS | Pays |
|---|---|---|---|
| $17.32 | 694.97% |
US
|
|
| $-7.98 | -466.27% |
US
|
|
| $-5.29 | -342.81% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 1,173.24% |
NL
|
